Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06883526 | NOT YET RECRUITING | Lymphoma

Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Sponsor:

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Brief Summary:

PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.

Condition or disease

Lymphoma

Intervention/treatment

ZG005 for Injection

Gecacitinib Hydrochloride Tablets

Phase

PHASE1

PHASE2

Study Type : INTERVENTIONAL
Estimated Enrollment : 60 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Actual Study Start Date : 2025-05
Estimated Primary Completion Date : 2027-04
Estimated Study Completion Date : 2027-05

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Fully understand this study and voluntarily sign the ICF；
  • * Age ≥18 at ICF signing, regardless of gender；
  • * Histologically confirmed relapsed or refractory lymphoma.
Exclusion Criteria
  • * Lymphoma with known CNS involvement；
  • * Severe cardiovascular/cerebrovascular diseases.
  • * Any other reason deeming the participant unsuitable for the study, as judged by the investigator.
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

Location Details

NCT06883526

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

China, Zhejiang

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China,